We evaluated the @entity3787 radical (* @entity2145 ) scavenging action of nonsteroidal anti-inflammatory drugs (NSAIDs), @entity11141 (SA), @entity3522 and @entity12698 in Fenton's reaction and their neuroprotective effects in @entity9013 ( @entity9016 )-induced striatal @entity935 (DA) depletion in @entity35 . @entity2697 hydroxylation procedure employing HPLC-electrochemistry was used to assay formation of * @entity2145 in Fenton's reaction in test tubes. While SA dose- and time-dependently hydroxylated itself and inactivated * @entity2145 , @entity12698 (up to 10 mM) showed no effect on * @entity2145 formation and @entity3522 caused a reduction in * @entity2145 generation only at high doses (100 microM-10 mM). Administration of the non-selective cyclooxygenase (COX) inhibitor, SA (50, 100 mg/kg, i.p.) significantly attenuated striatal DA depletion caused by intrastriatal infusion of @entity9016 (100 nmol in 4 microl). Treatment with another nonselective, reversible COX inhibitor, @entity3522 (5, 10 mg/kg) did not protect against @entity9016 -induced DA depletion. The selective @entity4665 inhibitor, @entity12698 (2.5-50 mg/kg) treatment exacerbated @entity9016 -induced decrease in DA. Failure of @entity12698 or @entity3522 to render protection in animals against @entity9016 -induced DA depletion indicates absence of @entity3009 involvement in @entity9016 action. These results also suggest that the neuroprotective ability of SA is independent of @entity3009 mediation. A relationship between inactivation of * @entity2145 by SA and its ability to protect DA depletion in the striatum caused by @entity9016 indicates a direct involvement of * @entity2145 in the action of this neurotoxin. The present study establishes potent neuroprotective activity of SA and suggests the use of @entity117 in adjuvant therapy in @entity191 .

Non-steroidal anti-inflammatory drug @entity11141 , but not @entity3522 or @entity12698 , protects against XXXX -induced dopaminergic neurotoxicity in @entity35 .

@entity4665 :: ('26198(Tax:10116)', 'Gene') :: ['COX-2'] @entity12698 :: ('MESH:C105934', 'Chemical') :: ['celecoxib'] @entity3522 :: ('MESH:D004008', 'Chemical') :: ['diclofenac'] @entity2697 :: ('CHEBI:30762', 'Chemical') :: ['Salicylate'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity11141 :: ('MESH:D012980', 'Chemical') :: ['sodium salicylate'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity3009 :: ('CHEBI:26333', 'Chemical') :: ['prostaglandin'] @entity3787 :: ('MESH:D017665', 'Chemical') :: ['hydroxyl'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease"] @entity35 :: ('10116', 'Species') :: ['rats'] @entity9016 :: ('CHEBI:34761', 'Chemical') :: ['MPP(+)'] @entity9013 :: ('MESH:D015655', 'Chemical') :: ['1-methyl-4-phenylpyridinium'] @entity2145 :: ('MESH:C031356', 'Chemical') :: ['OH']
@entity9013 :: (MESH:D015655,Chemical) :: ['1-methyl-4-phenyl pyridinium']
